We are excited to bring out the ABX-2 topic on the treatment of uncomplicated cystitis and skin & soft tissue (SSTI) infections. The new charts in this newsletter will support our spring academic detailing discussions with providers in Saskatchewan. Our discussions on ABX-1 were very well received and we know many of you made use of the extra support tools such as the "Gone Viral?" office/clinic posters and the patient friendly "Viral Prescription Pad". These are all available at www.RxFiles.ca/abx.

**ABX-2: A FEW PEARLS FROM INSIDE THAT CAUGHT OUR EYE...**

**UNCOMPROMISED CYSTISIS** - Page 2 - 3

1) **Staying Power**: > 60 years & still 96% or better!

Susceptibility of *E. coli*, the most common urinary pathogen, to nitrofurantoin (MACROBID) remains at 96% or better in Saskatchewan (per recent antibiograms).

2) **60% - Are you kidding?!**

In some institutional settings, like long-term care, *E. coli* resistance to ciprofloxacin can be as high as ~60%. No wonder antimicrobial stewardship messaging suggests “Reserve to Preserve” for when we really need it!

3) Urine cultures are not required - for most symptomatic acute uncomplicated cystitis. Empiric antibiotic Rx is suitable based on patient symptoms (e.g. dysuria, frequency) & history.

**SKIN and SOFT TISSUE INFECTIONS** - Page 4 - 8

4) Incision and Drainage (I&D) - key to successful treatment of skin abscess.

ABX just don’t penetrate abscesses very well. I&D alone results in cure >80% of the time.

5) Elevation of the affected limb, e.g. above level of the heart - often essential in the successful treatment of cellulitis.

6) **My name is clindamycin - I usually play 3rd line**.

For most SSTI, resistance to clindamycin, and safety are major concerns. There are usually better options.

**BETAS LACTAM ALLERGY and ANTIBIOTIC HARMs** - Page 9 - 10

7) If you test 1000 patients with penicillin "allergy", only ____ will have a true IgE mediated allergy (e.g. anaphylaxis).

Know your options! (see pg 9)
Treatment Approach For Acute, UNCOMPLICATED Cystitis in Women

- Nitrofurantoin is a good empiric first choice as it has retained excellent susceptibility (96% Outpatient Regina, Saskatoon) to *Escherichia coli* despite ~65 years of use [see Table 2].
- In SK, TMP/SMX is a suitable alternative in those with uncomplicated, 1st episode cystitis and without UTI or antibiotic use in the past 3-6 months [see Table 3].

**Table 2: Empiric Drug Regimen(s) of Choice**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosage</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nitrofurantoin</td>
<td>100mg po BID</td>
<td>x5 d $19</td>
</tr>
<tr>
<td>MACRODANTIN</td>
<td>50-100mg po QID</td>
<td>x5 d $20-29</td>
</tr>
<tr>
<td>Nitrofurantoin</td>
<td>50-100mg po QID</td>
<td>x5 d $14-16</td>
</tr>
</tbody>
</table>

**Table 3: Alternative Regimens**

- TMP/SMX
  - 1 DS tab po BID (1DS tab=160/800mg) x3d $31
  - option depending on local resistance & if recent history of UTI/antibiotics
  - 1 SS tab if BID if CrCl 15-30mL/min
- Trimethoprim, g
  - 200mg po daily x3d $32
- Cephalexin, g
  - 250mg po QID x7d $37
- Fosfomycin, g
  - Suspension (powder sachet; dissolve in ½ cup water); single dose x1d $38
- Amoxicillin/ clavulanate, g
  - 875/125mg po BID x7d $319
- Ciprofloxacin, g
  - 250mg po BID x7d $315
- Norfloxacin, g
  - 400mg po BID x3 d $34

*Caution: potential T K ‘drug interactions **Higher doses of ciprofloxacin used if pyelonephritis (i.e., 500 mg po BID) (Note: fosfomycin, nitrofurantoin, norfloxacin & moxifloxacin – should not be used if pyelonephritis is suspected)

**No role for follow-up culture (“test of cure”) if patient asymptomatic.**

**Treatment Evidence Summary**

Antibiotics are recommended for symptomatic cystitis. In 2 RCTS (n=884, n=78), placebo was associated with prolonged symptoms & a small risk of progression to pyelonephritis (0.4-2.6%, NS vs antibiotic), but also resulted in clinical cure 25-42% of the time. With antibiotics, symptom relief may be expected within 36-48 hours.

Nitrofurantoin x5-7 days has similar effectiveness to alternative regimens. In RCTS, there was no difference in clinical cure rates vs TMP/SMX x3-7 days, ciprofloxacin x3 days, & fosfomycin x1 dose. Nitrofurantoin x3 days is not recommended as this regimen resulted in less clinical/bacterial cure than TMP/SMX x3 days (NNH=5). Short courses of nitrofurantoin are well tolerated (however, urine color often darkens). SAESs (e.g. pulmonary toxicity, peripheral neuropathy, hepatic, & hemolytic) are rare with short term therapy (≤14 days). With prophylactic therapy, 2 meta-analyses of controlled trials (N=12, n=1063; N=17, n=511) have reported 2 cases of pulmonary toxicity. Surveillance data have reported SAESs in less than 0.003% of nitrofurantoin courses.

---

**Pearls for the Management of UNCOMPLICATED Cystitis in Women:**

- Urine culture is not required in most acute, uncomplicated cystitis and asymptomatic bacteriuria (“Symptom-Free Pee, Let It Be”) [see also Geri-RxFiles].
- Consider nitrofurantoin as empiric drug of choice except if CrCl <30 mL/min.
- Consider TMP/SMX as a suitable alternative to nitrofurantoin in those with low risk of resistant bacteria (e.g. no history of UTI or antibiotic use in the past 3-6 months).
- If bacteria is resistant to nitrofurantoin and TMP/SMX, consider fosfomycin.
- “Test of cure” is not recommended following treatment if patient asymptomatic.
- Prior to initiating prophylactic antibiotics in recurrent cystitis, encourage sexually active women to avoid spermicide & consider an alternative form of contraception.

**Pre-Treatment Consideration**

⇒ Urine culture is rarely required in uncomplicated & only local symptoms!
- Symptoms (e.g. dysuria & frequency) associated with high probability of cystitis.4
- Urine culture is typically required in the following patients:
  - Recent (e.g. <3-6 month) hospitalization or travel outside Canada/USA
  - Early recurrence of cystitis (i.e. less than ~1 month)
  - Previous non-*Escherichia coli* gram negative organism or previous ESBL cystitis
  - Complicated UTI (see Table 1), pyelonephritis suspected, or pregnancy

**Most Common Pathogen & Susceptibility Concerns (Outpatient/Community) 9-10**

- *Escherichia coli* por-ESBL is the most common pathogen (75-95% of cystitis cases).
  - Susceptibility to nitrofurantoin in SK: 96% Regina2016, 96% Saskatoon2015
  - Susceptibility to TMP/SMX in SK: 76% Regina2016, 77% Saskatoon2015
  - Susceptibility to ciprofloxacin in SK: 83% Regina2016, 85% Saskatoon2015
  - A local resistance of >20% for TMP/SMX often serves as an arbitrary cut off for empiric antibiotic choice.5,10A,10B
  - A localized resistance to ciprofloxacin is much lower in LTC (55% Regina, 40% Saskatoon).
  - Less common pathogens: other Enterobacteriaceae organisms (e.g. Klebsiella species, Proteus mirabilis), Staphylococcus...

**Table 1: Factors that Would Classify a UTI as “Complicated”**

<table>
<thead>
<tr>
<th>Anatomic abnormality</th>
<th>Cystocele, diverticulum, fistula</th>
</tr>
</thead>
<tbody>
<tr>
<td>Iatrogenic</td>
<td>Indwelling catheter (catheter removal often curative!)</td>
</tr>
<tr>
<td>Voiding dysfunction</td>
<td>Vesicoureteric reflux, neurologic disease</td>
</tr>
<tr>
<td>Urinary tract</td>
<td>Bladder outlet obstruction, ureteral stricture, ureteropelvic junction obstruction, urolithiasis</td>
</tr>
</tbody>
</table>

* May sometimes be considered as complicated: surgery, incontinence, pregnancy, diabetes (especially if long-term complications i.e. neuropathy), males, immunosuppression.

⇒ Urine culture is NOT indicated in most asymptomatic patients, as there is no benefit and potential harm (e.g. resistant bacteria) with antibiotic treatment.

(Exceptions: pregnancy or those awaiting urinary surgery/manipulation).7,8

**UNCOMPLICATED CYSTITIS IN WOMEN – MANAGEMENT CONSIDERATIONS**

---

*online extras* $ dose for renal dysfx $ Exception Drug Status SS $ recovered NIH $ prior approval NIH $ AHR adjusted hazard ratio AE = adverse events CCI = contraindication CUA = Canadian Urological Association DS = double strength DS = double strength (105 tab=160/800mg) eGFR = estimated glomerular filtration rate ESBL = extended spectrum beta-lactamases (highly resistant Gram-negative bacterial) eGFR = estimated glomerular filtration rate Gm-ve = gram negative HS = bedside IDSA = Infectious Diseases Society of America LTC = long-term care N = number needed to harm NNT = number needed to treat NS = non-statistically significant OR = odds ratio RCT = randomized controlled trial SAE = serious adverse events SK = Saskatchewan SOGC = Society of Obstetricians and Gynaecologists of Canada SS = single strength (155 tab=80/400mg) TMP/SMX = trimethoprim/sulfamethoxazole UTI = urinary tract infection

---

www.RxFiles.ca © Apr 2017

Pg 2
**Clinical Q&A**

**Nitrofurantoin: Is nitrofurantoin suitable for those with reduced renal function?**

- In adults ≥65 years, nitrofurantoin recommendations were revised from CrCl ≥60 ml/min Beers 2012 to now recommend use in patients with CrCl of ≥30 ml/min Beers 2015. Two retrospective studies (n=21,317, n=356) were conducted using the Modified Cockcroft-Gault (MCG), Elderly-Adjusted MCG, and/or Modification of Diet in Renal Disease (MDRD) equations to calculate renal function. There was no difference in clinical cure; however, 1 study demonstrated greater SAE (e.g., pulmonary reactions leading to hospitalization) in those with eGFR <50 ml/min/1.73m² vs eGFR ≥ 50 ml/min/1.73m² (aHR 4.13, 95% CI 1.31-13.09). Studies are limited by the number of patients included with renal function <50 ml/min (n=187/21,317 (0.9%))%, n=72-193/356 (20-54%) depending on equation²⁹.

**Fosfomycin: What is its role in uncomplicated cystitis?²⁵-²⁸**

- Low rate of resistance seen, even for ESBLs and *Pseudomonas* species. However, resistance concerns have arisen in some countries (e.g. Spain) with more extensive use. Thus, reserve in order to preserve activity for more resistant cases.
- Reasonable to consider use when nitrofurantoin & TMP/SMX are not an option.

**Trimethoprim (TMP): Does trimethoprim have same resistance pattern as TMP/SMX?**

- If a bacteria is resistant to TMP/SMX, it would also be resistant to TMP alone.
- When SMX is CI (e.g. sulfa allergy, pregnancy 3rd trimester), TMP monotherapy may be used. European experience suggests similar resistance patterns and clinical effectiveness to TMP/SMX²⁹⁻³³.

**Which “complicated” patients may be appropriate for “short course” therapy?**

- Healthy, community-dwelling post-menopausal women, people with diabetes & no long-term complications (e.g. neuropathy), & pregnant woman with cystitis may be successfully treated with “short-course” therapy.²⁸⁻³⁷

---

**Cystitis: Managing recurrence**

**Definitions**

- **Relapse:** Original organism re-appears within 2 weeks of completing therapy.
- **Reinfection:** Different organism (generally) presents after 2 weeks of therapy.
- **Recurrence:** Defined as at least 2 uncomplicated, culture-positive UTIs in 6 months or at least 3 in 12 months. Recurrence may sometimes be related to an anatomical cause (incomplete bladder emptying, bladder cancer, etc.) & warrant further investigation.

**How does acute treatment change in recurrent infections?**

- If recurrence occurs within ~30 days, obtain a urine culture, and rule out pyelonephritis. Consider using a different empiric antibiotic than previous, as presence of resistant bacteria is more likely. If previous 3 day course, may treat for 7.
- If recurrence occurs after ~30 days, a urine culture is likely not necessary. It is reasonable to use the same 1st line empiric antibiotic, as with the initial cystitis episode, if patient previously responded.

**Table 4: Oral Regimens – Recurrent Cystitis Therapy**

<table>
<thead>
<tr>
<th>Acute self-treatment</th>
<th>Consider in patients able to recognize symptoms. Prescribe to have on hand at home for first onset of symptoms.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nitrofurantoin * MACROBID</td>
<td>100mg po BID x 5 days - high concordance between self-diagnosis &amp; culture in appropriately selected patients.</td>
</tr>
<tr>
<td>TMP/SMX</td>
<td>1 DS tab (160/800mg) po BID x 3 days - advise patients to contact provider if symptoms do not resolve/improve within 48 hours despite therapy</td>
</tr>
<tr>
<td>Ciprofloxacin ** ▼</td>
<td>250mg po BID x 3 days</td>
</tr>
<tr>
<td>Post-coital Prophylaxis</td>
<td>Consider in patients when cystitis routinely presents within 24-48 hours of intercourse.</td>
</tr>
<tr>
<td>TMP/SMX</td>
<td>½ SS tab (40/200mg) po x1 - post-coital approaches (i.e. single dose taken within 2 hours of intercourse) result in less antibiotic use than continuous approaches</td>
</tr>
<tr>
<td>TMP</td>
<td>100mg po x1</td>
</tr>
<tr>
<td>Nitrofurantoin *</td>
<td>50-100mg po x1</td>
</tr>
<tr>
<td>Cephalexin ***</td>
<td>250mg po x1</td>
</tr>
<tr>
<td>Ciprofloxacin ** ▼</td>
<td>125mg po x1</td>
</tr>
<tr>
<td>Norfloxacin ** ▼</td>
<td>200mg po x1</td>
</tr>
</tbody>
</table>

**Continuous Prophylaxis**

<table>
<thead>
<tr>
<th>Consider option; however, increased concern for AE &amp; impact on bacterial resistance. Consider stopping in 6-12 months.</th>
</tr>
</thead>
<tbody>
<tr>
<td>TMP/SMX</td>
</tr>
<tr>
<td>TMP</td>
</tr>
<tr>
<td>Cephalexin ***</td>
</tr>
<tr>
<td>Nitrofurantoin *</td>
</tr>
<tr>
<td>Nitrofurantoin/MACRODANTIN MACROBID</td>
</tr>
</tbody>
</table>

**Prophylaxis:** initiate after UTI eradication (confirm with a negative culture 1-2 wks post-treatment).²⁸⁻³⁷

- If choosing nitrofurantoin, either Nitrofurantoin/MACRODANTIN, g 50-100mg or MACROBID 100mg are reasonable.
- Beers 2015 recommends avoiding long-term use of nitrofurantoin in those ≥65 years due to adverse effects (e.g. pneumonitis, peripheral neuropathy).²³ Low Quality Evidence, Strong Recommendation.²³ (see Nitrofurantoin Q&AsB).
- Reserve fluoroquinolones due to resistance concerns & serious rare AE (e.g. on tendons, muscles, nerves/CNS). The FDA generally considers risk to be greater than the benefits if used for uncomplicated UTI.²³
- Strength of cephalexin may require splitting the non-scored 250mg tablet (e.g. pill-cutter).

---

*Strength of evidence varies according to the table inclusion criteria. References are provided in the original text. All medications are available in Canada. Non-steroidal anti-inflammatory drugs (NSAIDs) are not included in this table.*
PEARLS for the MANAGEMENT of SSTI Treatment & Antibiotic Stewardship

- Incision & drainage (I&D) is key to successful treatment of purulent skin infections!
  - incision & drainage alone (i.e. without antibiotics) is often sufficient for clinical cure
- Avoid long durations of antibiotic treatment (e.g. >10days); 5 days is often adequate.
- Resolution of skin inflammation takes time & continues after antibiotic stopped
- Elevation of an affected limb is usually essential for successful cellulitis therapy.
- Before treating, consider type of infection, risk for Staph, & if CA-MRSA is likely.
- Consider TMP/SMX or doxycycline over clindamycin for CA-MRSA, due to local resistance concerns & adverse events associated with clindamycin.
- Topical antibiotics are as effective as oral antibiotics for limited & localized impetigo.

OVERVIEW & PRE-TREATMENT CONSIDERATIONS

<table>
<thead>
<tr>
<th>Non-Purulent</th>
<th>Purulent (e.g. Pus)</th>
</tr>
</thead>
<tbody>
<tr>
<td>e.g. non-bullous impetigo, non-purulent cellulitis</td>
<td>e.g. bullous impetigo, carbuncles, cutaneous abscess, folliculitis, furunculosis, purulent cellulitis</td>
</tr>
<tr>
<td>Simple skin infections, including cellulitis, are Gram-positive infections!</td>
<td></td>
</tr>
</tbody>
</table>

Think predominantly **Strep**!

**Incision & Drainage (I&D)**: is key to successful treatment of purulent skin infections!
- I&D cornerstone of treatment as antibiotics poorly penetrate pus. Consider swabbing the drainage/exudate on all moderate to severe infections on the initial visit, especially if potential MRSA. However, avoid initiating antibiotics based on the C&S if the infection is improving. I&D alone often adequate. May add antibiotics if ↑ risk (e.g. abscess >5cm, systemic symptoms, extensive surrounding cellulitis).

Think predominantly **Staph**!

**Risk factors for CA-MRSA**
- **Age**: <2 years old & >65 years old
- **Athletes** (mainly contact sports)
- **Men who have sex with men**
- **Persons living in correctional facilities**
- **History of colonization or recent infection with CA-MRSA**
- **Antibiotic use in the past 6 months**
- **Recent invasive procedures e.g. dialysis**
- **IV drug use**
- **Military personnel**
- **Homeless persons**
- **Prior hospitalization for SSTI (check MRSA screen from hospital if available)**
- **Trauma associated**
- **Of note, SSTIs often respond to therapy that does not cover CA-MRSA, even if CA-MRSA is endemic or cultured. Empiric CA-MRSA coverage may not be essential.**
- **There are no reliable signs/symptoms to distinguish CA-MRSA from other purulent SSTIs.**

**Is there a role for over-the-counter topical antibiotics in treating impetigo?**
- Reserve topical antibiotics for infections (e.g. impetigo). Overuse for non-infectious conditions (e.g. rash) has led to resistance with these agents.
- There is limited evidence that bacitracin, gramicidin, neomycin &/or polymyxin B & fusidic acid have FUDID, when pathogens were sensitive to these agents.
- Unpublished in vitro Saskatchewan data suggests POLYSPORIN TRIPLE OINTMENT, g x 4 (bacitracin, gramicidin, polymyxin B; $15-$20) can be considered in areas with local resistance concerns to mupirocin or fusidic acid.

**Most Common SSTI Pathogens & Susceptibility Concerns**

**Group A Streptococcus**, or “GAS”
- Likely if non-bullous impetigo, cellulitis without pus/lymphangitis

**Staphylococcus aureus**
- MSSA: methicillin-sensitive *Staph. aureus* (i.e. sensitive to cloxacillin in Canada)
- MRSA: methicillin-resistant *Staph. aureus* (not susceptible to β-lactam antibiotics)
  - in SHR & RQHR, approximately ⅓ of isolates are MRSA
  - CA-MRSA: community associated MRSA
    - onset in community & without health-care associated risk factors
    - in SHR & RQHR, good susceptibility (≥92%) to doxycycline or TMP/SMX; less susceptibility to clindamycin for MRSA (50-88%)
- HCA-MRSA: health care associated MRSA

**When is it necessary to cover for CA-MRSA if suspecting a *Staphylococcal* cause?**
- Coverage for CA-MRSA may be recommended if:
  - patient is from a highly endemic region for CA-MRSA
  - CA-MRSA risk factors are present (see Table 1)
  - clinical judgement warrants (e.g. patient follow-up unreliable, immunocompromised, seriousness of infection, etc.)
  - lack of improvement on a beta-lactam or systemic symptoms

**Risk factors for CA-MRSA**

- **Age**: <2 years old & >65 years old
- **Athletes** (mainly contact sports)
- **Men who have sex with men**
- **Persons living in correctional facilities**
- **History of colonization or recent infection with CA-MRSA**
- **Antibiotic use in the past 6 months**
- **Recent invasive procedures e.g. dialysis**
- **IV drug use**
- **Military personnel**
- **Homeless persons**
- **Prior hospitalization for SSTI (check MRSA screen from hospital if available)**
- **Trauma associated**
- **Of note, SSTIs often respond to therapy that does not cover CA-MRSA, even if CA-MRSA is endemic or cultured. Empiric CA-MRSA coverage may not be essential.**
- **There are no reliable signs/symptoms to distinguish CA-MRSA from other purulent SSTIs.**

**Is there a role for over-the-counter topical antibiotics in treating impetigo?**
- Reserve topical antibiotics for infections (e.g. impetigo). Overuse for non-infectious conditions (e.g. rash) has led to resistance with these agents.
- There is limited evidence that bacitracin, gramicidin, neomycin &/or polymyxin B & fusidic acid have FUDID, when pathogens were sensitive to these agents.
- Unpublished in vitro Saskatchewan data suggests POLYSPORIN TRIPLE OINTMENT, g x 4 (bacitracin, gramicidin, polymyxin B; $15-$20) can be considered in areas with local resistance concerns to mupirocin or fusidic acid.
IMPETIGO
MOST COMMON PATHOGENS:
- Non-bullous (“honey-crusted”, 70% of cases): Group A Streptococcus
  Staphylococcus aureus (usually MSSA)
- Bullous (30% of cases): Staphylococcus aureus (usually MSSA)

EMPIRIC DRUG REGIMEN OF CHOICE:
- A topical antibiotic is preferred if the infection is limited & localized (i.e. 2-3 small areas). Crusts do not need to be removed prior to applying.
- An oral antibiotic is preferred if the infection is unresponsive to topical antibiotics (i.e. no improvement after 24-48 hours), recurrent or widespread (i.e. numerous or large lesions), or during an outbreak; or if the patient has constitutional symptoms suggesting bacteremia, a fever, lymphadenopathy, valvular heart disease, is immunocompromised, or <1 month old.
- Duration of therapy is generally 5 to 7 days.

<table>
<thead>
<tr>
<th>TOPICAL ANTIBIOTICS preferred if limited &amp; localized infection</th>
<th>ADULT DOSING</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mupirocin 2% ointment or cream BACTROBAN, g $22</td>
<td>Apply sparingly to lesions TID</td>
</tr>
<tr>
<td>Fusidic acid 2% ointment or cream FUCIDIN $34</td>
<td>Apply sparingly to lesions TID to QID</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ORAL ANTIBIOTICS see above for when oral preferred over topical</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cephalexin 50-100mg/kg/day PO ÷ QID 500mg PO QID</td>
<td></td>
</tr>
<tr>
<td>Cloxacillin 50mg/kg/day PO ÷ QID 500mg PO QID</td>
<td></td>
</tr>
</tbody>
</table>

PENICILLIN ALLERGY: TYPE I HYPERSENSITIVITY (i.e. anaphylaxis)
- Erythromycin*¶ 30-40mg/kg/day PO ÷ QID 250-500mg PO QID
- Clindamycin ¶ 15mg/kg/day PO ÷ TID-QID 300-450mg PO TID

*Erythromycin is the most studied macrolide, but azithromycin or clarithromycin may also be used
¶Monitor clinical response due to potential resistance concerns

If a swab was done & the culture only shows Streptococcus:
- penicillin V 25,000-90,000 units/kg PO ÷ QID or 300-600mg PO QID

IMPETIGO DUE TO MRSA (less common):
- Topical antibiotics: consider mupirocin if no local resistance concerns
- Oral antibiotics: consider TMP/SMX or doxycycline (see page 6 for dosing)
  - will cover MRSA but has poor/no coverage of Group A Streptococcus

TREATMENT EVIDENCE FOR CLINICAL CURE:
Based on a 2012 Cochrane Review of 68 RCTs with N=5,578:
- Topical mupirocin & fusidic acid had similar efficacy (4 RCTs, n=440; RR 1.03, 95% CI 0.95-1.11).
- Topical mupirocin or fusidic acid were equally effective as oral antibiotics (22 RCTs, n=884); however, studies are lacking in those with more extensive impetigo.
  - topical mupirocin was slightly superior to oral erythromycin (10 RCTs, n=581; RR 1.07, 95% CI 1.01-1.13)
- Combining a topical & oral antibiotic failed to show additional benefit over a topical antibiotic alone (1 RCT, n=49).

FOLLICULITIS/FURUNCULOSIS/CARBUNCLE
MOST COMMON PATHOGENS: Staphylococcus aureus (usually MSSA)

TREATMENT APPROACH – FOLLICULITIS / FURUNCULOSIS:
- If limited involvement or small pustule size (1-2mm): usually self-limiting; hot compresses & anti-septic cleanser may be beneficial (e.g. chlorhexidine)
- If extensive infection or above ineffective: topical antibiotic
  - mupirocin 2% ointment or cream BACTROBAN, g TID x 7 days
  - fusidic acid 2% ointment or cream FUCIDIN TID to QID x 7 days

TREATMENT APPROACH – CARBUNCLE: see purulent cellulitis (page 6) for antibiotics
- Incision & drainage (I&D), hot compresses & anti-septic cleanser (e.g. chlorhexidine)
- Consider systemic antibiotics in addition to I&D if: large (diameter ≥5cm) &/or multiple abscesses, extensive surrounding cellulitis, located in area difficult to drain (e.g. face, groin), constitutional symptoms or fever, debilitated elderly, immunocompromised, diabetic, or active cancer.
- Duration of therapy is generally 5 to 7 days.

ABSCESS, CUTANEOUS
MOST COMMON PATHOGENS: Staphylococcus aureus (usually MSSA)
- rarely Streptococcus, anaerobes, or polymicrobial

TREATMENT APPROACH:
- Incision & drainage (I&D):
  - for simple abscess (<5cm), I&D alone is often adequate
  - From Choosing Wisely Canada: Antibiotics usually do not help simple abscesses heal faster. Usually, draining a simple abscess is enough to heal the infection. In most cases, giving antibiotics does not help heal the infection any faster than just draining the abscess.
- Antibiotic therapy generally only indicated if: see purulent cellulitis (page 6) for treatment options
  - large abscesses (>5cm), extensive cellulitis, unresolved SSTI or rapid progression
  - abscess in area where I&D is difficult (e.g. face, hands, genitalia)
  - systemic illness symptoms e.g. ↑ temperature, respiratory rate, heart rate, WBC
  - significant comorbidities, immunosuppression, very young or very old

TREATMENT EVIDENCE: I&D ± ANTIBIOTICS in UNCOMPROMISED SKIN ABSCESSES
- A meta-analysis of 4 RCTs with N=589 patients found no difference in clinical cure rates when I&D + antibiotics was compared to I&D alone. Antibiotics provided a non-statistically significant reduction in recurrence.
- A recent RCT with N=1,265 patients who underwent I&D ± TMP/SMX 2 DS tablets BID x 7 days, found the addition of antibiotics resulted in:
  - a modest improvement in clinical cure (NNT=14, TMP/SMX 80.5% vs placebo 73.6%, 95% CI 2.1-11.7)
  - a similar NNH for gastrointestinal adverse events (NNH=15, TMP/SMX 42.7% vs placebo 36.1%, note: p-value & CI not provided)
  - no difference in the rate of invasive infections
### Non-Purulent Cellulitis

- Cellulitis with no purulent drainage, exudates, or abscess

#### Most Common Pathogens: Group A Streptococcus

- Staphylococcus aureus is less common (of which, ~⅔ of isolates in SHR & RQHR are MSSA)

#### Treatment approach for Non-Purulent Cellulitis

- Elevation of an affected limb is usually essential for successful therapy

<table>
<thead>
<tr>
<th>Pediatric Dose</th>
<th>Usual Adult Dose</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cephalexin</td>
<td>50-100mg/kg/day PO ÷ QID</td>
<td>500mg PO QID</td>
</tr>
<tr>
<td></td>
<td>8-12mg/kg/day (TMP) PO ÷ BID if &gt;1 month old OR ≥9 years: 4mg/kg/day PO ÷ BID</td>
<td>1-2 DS tab PO BID OR 100mg PO BID</td>
</tr>
<tr>
<td>Doxycycline</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clindamycin</td>
<td>20-40mg/kg/day PO ÷ TID to QID</td>
<td>300mg PO QID or 450mg PO TID</td>
</tr>
<tr>
<td>Erythromycin</td>
<td>30-40mg/kg/day PO ÷ BID</td>
<td>250mg PO QID or 500mg PO BID</td>
</tr>
</tbody>
</table>

#### Penicillin Allergy: Type I Hypersensitivity (i.e. Anaphylaxis)

Avoid the below as empiric therapy, unless true penicillin allergy. Monitor response due to resistance rates.

### Purulent Cellulitis ± Abscess

- Cellulitis with purulent drainage or exudates in the absence of a drainable abscess

#### Most Common Pathogens: Staphylococcus aureus

- In SHR & RQHR, ~⅔ of isolates are MSSA; see page 4 for when to consider MRSA

#### Treatment approach for Purulent Cellulitis

- Elevation of an affected limb is usually essential for successful therapy

<table>
<thead>
<tr>
<th>Pediatric Dose</th>
<th>Adult Dose</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cephalexin</td>
<td>50-100mg/kg/day PO ÷ QID</td>
<td>500mg PO QID</td>
</tr>
<tr>
<td>Cloxacillin</td>
<td>50mg/kg/day PO ÷ QID</td>
<td>500mg PO QID</td>
</tr>
<tr>
<td>TMP/SMX</td>
<td>8-12mg/kg/day (TMP) PO ÷ BID if &gt;1 month old OR ≥9 yrs: 4mg/kg/day PO ÷ BID</td>
<td>1-2 DS tab PO BID</td>
</tr>
<tr>
<td>Doxycycline</td>
<td>≥9 yrs: 4mg/kg/day PO ÷ BID</td>
<td>100mg PO BID</td>
</tr>
</tbody>
</table>

#### Treatment Evidence for Both Non-Purulent & Purulent Cellulitis

**Duration of therapy:**

- For uncomplicated cellulitis (purulent & non-purulent), 5 days of therapy is as effective as 10 days providing clinical improvement by day 5. IDSA 2014

- Skin infections may worsen the first few days after I&D ± antibiotics are initiated. This worsening of the infection is part of the healing process & does not represent treatment failure. However, reassess management if systemic symptoms develop.

- reassure the patient that full inflammation / symptom resolution (i.e. skin healing) may take 1 to 2 weeks after antibiotics are stopped.

Cephalexin ± TMP/SMX for Uncomplicated Cellulitis without an Abscess

- Adding TMP/SMX to cephalexin in outpatients with cellulitis without an abscess failed to provide additional benefit compared to cephalexin alone:
  - RCT with n=146 patients without diabetes, immunosuppression, peripheral vascular disease or hospitalizations
  - conducted in an area endemic for CA-MRSA; ~5% had nasal MRSA colonization
  - weight based dosing for both cephalexin (500-1000mg QID) & TMP/SMX (SS QID to DS QID) x 7-14 days, but mean doses & duration not reported
  - the difference in cure rate was not statistically significant [cephalexin alone 82% vs cephalexin + TMP/SMX 85%, risk difference 2.7% (95% CI -9.3% to 15%)]
  - progression to abscess & adverse events were also not statistically significant

- Empiric therapy with cephalexin monotherapy is reasonable.

See following page for additional information on the TMP/SMX dose.
Treatment Evidence for both Non-Purulent & Purulent Cellulitis continued

Clindamycin vs TMP/SMX for Uncomplicated Skin Infections

- Cure rates, tolerability & discontinuation rates were similar between clindamycin vs TMP/SMX in a small patient population:
  - RCT with n=524 outpatients with uncomplicated skin infections (~53% cellulitis, ~30% abscess & ~16% mixed)
  - swabs were obtained for suppurrative lesions (57%); ~50% positive culture
  - ~41% S. aureus ~77% were MRSA, ~5% resistant to clindamycin
  - clindamycin 300mg TID vs TMP/SMX 2 DS tabs BID x 10 days
  - incision & drainage performed on all abscesses
  - the difference in cure rate was not statistically significant [clindamycin 89.5% vs TMP/SMX 88.2%, risk difference -1.2% (95% CI -7.6 to 5.1%)]
  - adverse events, including serious adverse events & discontinuation rates were similar between the groups
  - cure rates were similar when groups were stratified by cellulitis with or without an abscess
  - In Saskatchewan, TMP/SMX or doxycycline are preferred over clindamycin due to resistance concerns & adverse events (clindamycin community-associated C.diff RR 3.92).

What dose of TMP/SMX should be used for Staph aureus skin infections?

- Recent evidence suggests that patients with an uncomplicated S.aureus skin infections & a BMI ≤40kg/m² can be successfully treated with a standard dose of TMP/SMX (1 DS tablet BID). Consider high-dose TMP/SMX (2 DS tablets BID) in individuals with a BMI>40kg/m².
  - 1 double strength (DS) tablet = 160mg TMP / 800mg SMX
  - References often recommend 1 to 2 DS Tablets BID to QID, without guidance on selecting between the two doses. The most recent guidelines (2017 Sanford Guide) recommend 1 DS tablet BID with the caveat to use 2 DS tablets BID for patients with a BMI >40kg/m².
  - Recent “larger” RCTs that compared TMP/SMX to other treatment modalities used high-dose (2 DS tabs BID). However, smaller observational studies that compared standard to high-dose TMP/SMX collectively suggest standard dose is appropriate for those with a BMI ≤40kg/m²:
    - A 2011 prospective observational single center study concluded that high-dose TMP/SMX (2 DS tabs BID) failed to provide additional benefit in terms of clinical resolution compared to standard dose (1 DS tab BID) x 7-15 days in n=291 patients with MRSA skin infections (1 DS BID 75% vs 2 DS BID 73%, OR 0.96 [95% CI 0.76-1.2])
      - patients on high-dose TMP/SMX were more likely to have a trauma, & receive incision & drainage (the % of patients with an abscess was NS between the two groups)
      - results were similar for those who underwent I&D
      - both treatment groups had a similar BMI (30 vs 28kg/m², p=NS)
    - A small 2012 retrospective observational single center study (n=102) identified that morbidly obese patients (BMI>40kg/m²) were at greater risk of clinical failure when prescribed the standard dose of TMP/SMX (1 DS tab BID):
      - hospitalized for cellulitis with or without abscess
      - 94.8% received empiric IV antibiotics prior to stepping down to oral agents
    - Safety: hyperkalemia & nausea are dose-dependent, but the risk of SJS is not

Clinical Q&A

When should I consider MRSA decolonization?

- Routine decolonization is not recommended in the community due to a lack of short & long-term efficacy, and concerns regarding antibiotic resistance.
- Decolonization is of limited benefit as the relapse rate is very high (up to 75% at one year post decolonization), & even higher if the risk factors are not addressed at the same time of decolonization (e.g. poor hygiene, overcrowding).
- Consider patient referral to Infection Control &/or an Infectious Disease Specialist for decolonization.
- There may be some utility in patients who have recurrent infections (23 per 6 months) despite optimal wound care & proper hygiene, ongoing transmission among household contacts & other close contacts, or in those who are frequently hospitalized and have a high risk of complications if infection occurs.
  - Note, theoretically, decolonization may result in replacement of host MRSA strain with a more virulent subtype

How to obtain a specimen for culture & sensitivity

- consider swabbing moderate to severe purulent skin infections on the initial visit
  - routine swabbing of non-purulent skin infections is not recommended as cultures will grow normal skin flora
- ensure to swab the inside of the abscess cavity &/or purulent drainage / exudate, and not the superficial skin over the abscess
- label with specimen with the location & type of wound (e.g. “abscess, lower shin”)
- if the culture & sensitivity indicates a bacterial infection, avoid initiating antibiotics if the infection is improving (i.e. incision & drainage alone results in clinical cure in ~80% of cases)
- see RxFiles Online Extras for additional information on the incision & draining procedure and culturing skin infections

3 NON-DRUG MEASURES FOR SUCCESSFUL TREATMENT OF SKIN INFECTIONS

incision & drainage  
elevate affected limb

allow 2 to 3 weeks for inflammation to resolve

Skirt & Soft Tissue Infections Abbreviations

BMI=body mass index C&A=culture & sensitivity CA-MRSA=community associated MRSA CDC=Center for Disease Control CI=confidence interval DS=double strength generic GAS=Group A Streptococcus HCA-MRSA=health care associated MRSA I&D=incision & drainage IDSA=Infectious Diseases Society of America MRSA=methicillin-resistance Staphylococcus aureus MSSA=methicillin-sensitive Staphylococcus aureus N=number NS=non-statistically significant OR=odds ratio OTC=over-the-counter RCT=randomized controlled trial RR=Relative Risk RSR=reaction S.aureus=Staphylococcus aureus SHR=Saskatoon Health Region SS=Stevens Johnson Syndrome Staph=Staphylococcus Strep=Streptococcus ST=skin & soft tissue infection TMP/SMX=trimethoprim-sulfamethoxazole WBC=white blood count
A. INCISION AND DRAINAGE (I&D) PROCEDURE

Abscesses are localized infections of tissue marked by a collection of pus surrounded by inflamed tissue. Abscesses may be found in any area of the body, those requiring urgent attention are found on the extremities, face, buttocks, breast, perianal area, axilla, groin. Abscesses begin when the normal skin barrier is breached, and microorganisms colonize the underlying tissues. Causative organisms commonly include *Streptococcus sp.*, *Staphylococcus sp.*, enteric bacteria (perianal abscesses), or a combination of anaerobic and gram-negative organisms. Abscesses resolve by drainage. Smaller abscesses may resolve with conservative measures (warm soaks) to promote spontaneous drainage. Larger abscesses will require incision to drain them (I & D) as the increased inflammation, pus collection, and walling off of the abscess cavity diminish the effectiveness of antibiotic treatment. Healing following I & D should progress from the inside of the abscess outward to the incision site. For larger abscesses this may require a gauze packing to promote healing from the inside outward (See Part B below: Role of Packing for an Abscess).

NOTE:
- Extremely large abscesses that require extensive incision, debridement, or irrigation are best done in an operating room.
- Deep abscesses in very sensitive areas (labial, supraventricular, ischiorectal, perirenal) often require a general anesthetic to obtain proper exposure.
- Abscess in the hands or feet are best drained by a surgeon. Deep palm abscesses are a surgical emergency.
- Abscesses in the triangle formed by the bridge of the nose and the corners of the mouth should generally be treated with warm compresses and aggressive antibiotic therapy.
- Abscesses located near major vessels must be differentiated from aneurysms before I & D is performed to avoid fatal hemorrhage. The distinction is made through aspiration with a large bore needle, or with ultrasound guidance.

PROCEDURE
- The information below applies to an abscess within the skin and subcutaneous issue that is palpable.
- Obtain informed consent.
- Use Routine/Standard Infection Control Precautions, and sterile technique.

1. Infiltrate local anesthetic, allowing 2–3 minutes for anesthetic to take effect. Remember that tissue around an abscess is acrimon and local anesthetic is less effective. Consider doing a field block.
2. Incise over abscess with the scalpel blade, cutting through the skin into the abscess cavity. Follow skinfold lines whenever possible while making the incision. The incision should be sufficiently wide to allow the abscess to drain and to prevent premature closure of the incision.
   For smaller abscesses requiring incisions, a stab or cruciate incision should be adequate. Some refer to this as a puncture or stab technique since the operator inserts the tip of the scalpel directly into the center of the abscessed tissue without making a linear incision. If a culture is being obtained use the culture swab to take culture of abscess contents, swabbing inside the abscess cavity—not from the superficial skin over the abscess.
3. Use a hemostat or sterile cotton-tipped applicator to gently explore the abscess cavity to break up any loculations within the abscess.
4. Loosely pack the abscess cavity with the packing (if indicated).
5. Place gauze dressing over the wound and tape in place. Topical antibiotic is not required.
6. Schedule patient to return for review within 24–48 hours post-procedure. Depending upon the location of the abscess and size of the abscess, arrange for the packing material to be changed daily.
7. Pain from the site may require acetaminophen or nonsteroidal anti-inflammatory drugs; narcotics are rarely needed.

Following I & D of any abscess:
- Routine use of oral antibiotics after uncomplicated I & D is NOT recommended. Antibiotics have a role for patients with complicated abscesses (such as those with systemic symptoms), immunocompromised patients, and for abscesses with significant surrounding cellulitis or in area difficult to drain, such as the heel.
- The site should be observed for signs of recollection of pus or cellulitis.

- Complications of an inadequately treated abscess include bacteremia and septicaemia.
- In persons who are immunocompromised, particularly people with diabetes or peripheral arterial disease, an abscess on an extremity can be complicated by severe cellulitis or gangrene, with potential loss of the affected extremity.

Post-Procedure Patient Education:
- Patients should be instructed to watch for the following symptoms:
  - Recollection of pus in the abscess
  - Fever and chills
  - Increased pain and redness
  - Red streaks near the abscess
  - Increased swelling

References:
- Korniloff R. Technique of incision and drainage for skin abscesses. UpToDate. May 13, 2009;17.2

B. ROLE OF PACKING FOR AN ABSCESS

Packaging of wounds – there is no scientific evidence to support packing of wounds after I&D of a simple cutaneous abscess.

Studies (RCT) looking at outcomes from packing of simple abscesses are limited in number and of small size.

O’Malley et al demonstrated no difference in outcomes in patients who had I&D, standard wound irrigation and packing or no packing, however the packing group reported more pain and use of analgesics. There were no significant differences between groups in need for second intervention at 48 hours.

Packing of cutaneous abscesses is not usually done in developing countries with no significant problems. Clinical follow-up at 48 hours after I&D of simple cutaneous abscess is important whether wound is packed or not.

Reference:

C. CULTURING CELLULITIS

The diagnosis of cellulitis is based on the clinical features. Cellulitis associated with furuncles, carbuncles, or abscesses is usually caused by *S. aureus*. In contrast, cellulitis that is diffuse or associated with a defined portal most commonly caused by streptococcal species.

- For patients with nonpurulent cellulitis, cultures will usually grow normal skin flora and are therefore not routinely recommended.
  - Empirical therapy for infection due to beta-hemolytic streptococci is recommended.
  - Empirical coverage for MRSA may be considered in those with systemic signs and symptoms and is recommended in patients who do not respond to initial therapy.
- For patients with purulent cellulitis in the absence of a draining abscess, empirical drainage or exudate and send for culture.
  - Empirical therapy for infection due to beta-hemolytic streptococci is not likely necessary.
  - Empirical therapy for MRSA may be considered pending culture results.

Other microbiological investigations including aspiration and punch biopsies are not routinely recommended because results are rarely positive. Blood cultures are recommended when there are signs and symptoms of systemic illness.

References:
- Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children. Clinical Infectious Diseases 2011; 52:1-38
Of all the drugs on the market, beta-lactams (and penicillin in particular) seem to be most implicated in allergic reactions. However, such allergy is over-reported.

**Clinical Pearls**

1. Delayed rashes caused by penicillin, if after first few doses/days & no itchiness/hives, are not typically indicative of a true IgE-mediated allergy. A beta-lactam, such as a cephalosporin, can usually be given.
2. When possible, refer patients with uncertain penicillin allergy for **skin testing**. Skin testing is especially helpful when the allergy history is unclear, when the reaction took place >10 years ago, or when the reaction occurred days rather than hours after taking the antibiotic.
3. When the risk of true penicillin allergy is low, a **graded challenge** using a cephalosporin with a dissimilar side-chain is appropriate.

**Definitions**

- **Beta-lactams**: group of antibiotics with a distinctive beta-lactam ring; includes penicillins, cephalosporins, and carbapenems. Allergy may occur to either the beta-lactam ring (in which case a patient is allergic to all beta-lactams) or to the unique side chain (in which case the allergy is only to specific agents).
- **IgE**: immunoglobulin type E antibody. After encountering a specific antigen, IgE antibodies can trigger an immune response.
- **“True” IgE-mediated allergy**: potentially life-threatening reaction; also known as a type-I immediate hypersensitivity reaction. Symptoms are described below in “Management of Penicillin Allergy”. Anaphylaxis describes the most severe form of reaction.
- **Graded challenge**: some variation in approaches, but often a small dose of a potential allergen (e.g. 10% of the full dose) is given, followed by the full dose 1 hour later. (NOTE: in the in-patient setting, inappropriate consideration of penicillin allergy resulting in use of vancomycin or clindamycin may create suboptimal outcomes. Often a beta-lactam can be used. Take advantage of the inpatient status to confirm/monitor as necessary.)
- **Desensitization**: similar to the graded challenge, but at a slower pace (e.g. starting at 1/10,000 of the full dose). A sample protocol for an oral desensitization is here: [www.cdc.gov/std/tg2015/pen-allergy.htm](http://www.cdc.gov/std/tg2015/pen-allergy.htm) and an intravenous approach may be found in the Online Extras.
- **Penicillin skin-testing**: prick the skin with a minute quantity of penicillin; if a localized reaction not observed, an IgE-mediated allergy is unlikely.

**How likely is a beta-lactam allergy?**

<table>
<thead>
<tr>
<th>10,000 patients</th>
<th>If reaction occurred days rather than hours after taking the antibiotic, it is unlikely to be IgE-mediated.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1,000 patients</td>
<td>will report they have a penicillin allergy, 1</td>
</tr>
<tr>
<td>&lt;100 patients</td>
<td>will have a true IgE-mediated penicillin allergy, 2</td>
</tr>
<tr>
<td>1 to 3 patients</td>
<td>will have cephalosporin cross-reactivity, 3</td>
</tr>
<tr>
<td>1 patient</td>
<td>will have anaphylaxis when given penicillin, 4</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 1: Factors that decrease the likelihood of a true allergy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Skin test is negative</strong>: this provides a 97-99% certainty that the patient is not allergic. 5</td>
</tr>
<tr>
<td><strong>Age</strong>: 80% of patients with a reaction that occurred &gt;10 years ago will no longer be allergic to penicillin. 1</td>
</tr>
<tr>
<td><strong>Administration</strong>: reactions reported from oral administration are less likely to be true allergies.</td>
</tr>
<tr>
<td><strong>Symptoms</strong>: see below for how IgE-mediated symptoms differ from other beta-lactam reactions.</td>
</tr>
<tr>
<td><strong>Timing</strong>: if reaction occurred after days to weeks of taking antibiotic, it is unlikely to be IgE-mediated. 11</td>
</tr>
</tbody>
</table>

**Management of Penicillin Allergy**

After a reaction to penicillin, can a beta-lactam be prescribed in the future? The answer requires accurate differentiation between three types of beta-lactam adverse reactions.

- **Penicillin Adverse Event**
  - e.g. rash, GI upset, headache. A diffuse rash, which is not itchy, occurs in ≤10% of patients taking penicillin, usually after 2-5 days of therapy, and may last several weeks. These reactions are not IgE-mediated.
  - **An uncomplicated rash, a headache, or GI upset is not IgE-mediated, and so a cephalosporin or different penicillin may be prescribed.**
  - **Amoxicillin** has a high risk of rash when given during some viral infections, such as infectious mononucleosis (e.g. Epstein-Barr virus, cytomegalovirus); however this is **not** an allergy. 3

- **Serious Penicillin Adverse Event**
  - e.g. Stevens-Johnson syndrome, interstitial nephritis, hemolytic anemia, serum sickness*. These reactions usually occur >72hrs after beta-lactam dose. 7 They are not IgE-mediated.
  - **All beta-lactams are contraindicated.** Prescription of an alternative agent.
  - **Skin testing, desensitization, and graded challenges are all potentially harmful and not recommended**.

- **True IgE-Mediated Penicillin Allergy**
  - At minimum, presents as an itchy rash or hives. More severe symptoms include angioedema, hypotension, or bronchospasm. These reactions can be life-threatening and usually occur <1hr after taking a beta-lactam dose. 9-11 Anaphylaxis describes the most severe form of reaction.
  - **1. Skin test if possible**, especially if reaction was many years ago. **If the skin test result is negative, cephalosporins may be given safely & penicillins may be given with minimal risk.** **AMERICAN** 8
  - Consider administering the first dose via graded challenge if previous severe reaction. **If the skin test result is positive, OR skin testing is unavailable**, a cephalosporin graded challenge may be appropriate if patient factors described in Table 1 point away from IgE-mediated. A **cephalosporin with a dissimilar side chain is preferred** (see below).
  - **2. Otherwise**, prescribe an alternative agent.
  - **3. If no good alternative agents**, initiate a cephalosporin desensitization procedure.

  - **If allergy is likely IgE-mediated, skin test (if possible) using a cephalosporin with a different side chain than the cephalosporin that previously reacted.**

**Similar side chains (Canada):**

- penicillin VK and cefoxitin
- amoxicillin, ampicillin, cefadroxil, cephalexin, cefaclor, and cefprozil
- cefepime, ceftriaxone, and cefotaxime
- cefuroxime and cefoxitin
- ceftazidime and aztreonam

*Serum sickness reactions*: These are more common than the other serious reactions listed. Generally, these occur after 7-10 days of therapy and relate to immune complexes of IgG. Symptoms include urticarial vasculitis, renal dysfunction and joint pain. Skin testing is not helpful. Challenges and desensitization are contraindicated.
Antibiotics: Potential Harms

Antibiotics are a valuable resource and judicious use is very important. For many serious infections (e.g. pneumonia, bacterial meningitis, sexually transmitted infections) the benefits of antibiotics clearly outweigh potential harms. However, for conditions that are primarily viral (e.g. pharyngitis, acute sinusitis, acute bronchitis), the benefits are minimal and likely outweighed by harms.

Of note: antibiotic-related adverse drug events account for 1 out of every 5 visits to the Emergency Department.1

### Common Adverse Events

<table>
<thead>
<tr>
<th>Event</th>
<th>NNH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td>8-12</td>
</tr>
<tr>
<td>Yeast infection</td>
<td>23</td>
</tr>
</tbody>
</table>

- In a meta-analysis (10 trials, 2450 patients) comparing antibiotics to placebo for acute rhinosinusitis, common adverse events (such as nausea, vomiting, diarrhea, or abdominal pain) occurred in 27% of patients on antibiotics versus 15% on placebo (NNH = 8-12).2,5 The antibiotics used in this meta-analysis included penicillins, macrolides, and tetracyclines. Trials examining other populations have found similar numbers of adverse events.3,4,5
- A recent meta-analysis comparing amoxicillin or amox/clav to placebo found risk of yeast infection (candidiasis) ~ 8x higher in those on antibiotics (NNH = 23).6

### Allergic Reactions

- NNH from 20 (rash, hives) to 10,000 (anaphylaxis)

Allergic reactions can occur with any antibiotic; penicillin in particular is well studied. About 5-10% of patients will self-report a penicillin allergy;7,8 however the vast majority of these reactions are delayed reactions, occurring days to weeks after initiating therapy, and do not typically indicate a true allergy.9 Anaphylaxis occurs in about 0.01% of patients taking penicillin; about 10% of these reactions are fatal (i.e. 0.001% of all patients prescribed penicillin).10,11,12

### Serious Adverse Events

- NNH from 300 to 30,000

Rare but serious adverse events are associated with all antibiotics. Large, long-term randomized controlled trials are uncommon, and so it is difficult to put a precise estimate on how prevalent these events are. However, some adverse events include:
- **Clostridium difficile infection**: associated most often with clindamycin (RR=4), cephalosporins, and fluoroquinolones; risk varies depending on patient factors.13,14,15
- **Stevens Johnson Syndrome, Toxic Epidermal Necrolysis, & other severe skin reactions**: these events occur a few times per 100,000 antibiotic prescriptions.16 Cotrimoxazole in particular has a higher association than most other antibiotics.17
- **QT prolongation**: associated most often with macrolides (esp. clarithromycin and erythromycin) and fluoroquinolones (esp. levofloxacin and moxifloxacin). Risk of QT prolongation is also dependent on other factors (e.g. cardiac, metabolic, other drugs, etc.). See RxFiles QT Prolongation page 32 (11th Ed).
- **Tendon rupture with fluoroquinolones**: one large cohort study found a risk of 3.5% for tendon rupture in adults over the age of 65.18
- **Hyperkalemia with cotrimoxazole**: in older adults taking medications which can raise potassium (such as ACEIs, ARBs, spironolactone, or NSAIDs), cotrimoxazole was associated with sudden death (NNH ≈ 300).19,20
- **Contraceptive failure/drug interaction?** Although this is thought to be unlikely, there is a small but real risk & a backup birth control method is always recommended.

### Antibiotic Resistance

- NNH as low as 1???

Every course of antibiotic is likely to result in some emerging resistance which could affect the next choice of antibiotic regimen for that individual, especially if within 3 months of the previous antibiotic. Of course the NNH for catastrophic resistance would be much higher.

Resistance to an antibacterial can develop quickly. For example, strains of *Streptococcus pneumoniae* resistant to levofloxacin were documented in the same year levofloxacin was introduced to the market.21 Rare, but worrisome, reports of bacteria resistant to every available antimicrobial can be found in the literature.22

*The good news is that when prescribing patterns change, resistance rates decline.*23,24

Quotes from the team 😊: Harms speak louder when there is little or no benefit to offset them!
Important Definitions

- **Minimum Inhibitory Concentration (MIC):** the lowest concentration of an antimicrobial that prevents bacterial growth, but does not kill the organism.

- **Time vs Concentration Dependent Killing:** In time-dependent killing, an antimicrobial will be effective at any concentration above the MIC. A general rule of thumb is that serum levels should be above the MIC for > 50% of the dosing interval. In concentration-dependent killing, an antimicrobial is more effective at a higher dose. Thus achieving a high peak (e.g. >10x) relative to the MIC is ideal.

- **Bacteriostatic vs Bactericidal:** Bacteriostatic agents inhibit the further growth of bacteria. Bactericidal agents actively destroy existing bacteria. Classifications are not absolute - for example, agents may be bacteriostatic in most situations but bactericidal at high concentrations, or bacteriostatic against some organisms and bactericidal against others.

- **Gram staining:** Gram-positive bacteria appear purple under a Gram stain, due to retention of crystal violet dye in their thick peptidoglycan cell walls. Gram-negative bacteria appear red and have thinner cell walls.

- **Enterobacteriaceae bacteria:** e.g. Citrobacter, E. coli, Enterobacter, Klebsiella, Morganella, Proteus, Salmonella, Serratia, Shigella. Group of Gram-negative bacilli often found in the GI tract.

- **Anaerobic bacteria:** e.g. Peptococcus; Peptostreptococcus; B. fragilis; Prevotella. By definition, do not require oxygen to survive. Found as normal flora in the mouth and GI tract. Anaerobic coverage can be important in situations such as aspiration pneumonia, intra-abdominal infections, and diabetic foot ulcer.

- **MSSA & MRSA:** Staph aureus was originally susceptible to all penicillins. However, today Staph aureus is reliably resistant to penicillin, amoxicillin, and ampicillin through beta-lactamase production. In response, beta-lactamase-resistant antibiotics were invented, like methicillin, cloxacillin, and oxacillin. Further, beta-lactamase inhibitors like clavulanic acid were invented. Cloxacillin and amox-clav are able to kill methicillin-sensitive Staph aureus (MSSA). Unfortunately, Staph aureus resistant to methicillin (i.e., MRSA) soon emerged. MRSA is resistant to all beta-lactams; alternative agents must be used. Community-Associated MRSA (CA-MRSA) is defined as MRSA in patients who have not been hospitalized in the previous 12 months. CA-MRSA is less likely to be multi-drug resistant.

- **High-risk AECOPD:** presence of ≥ 1 of the following → severe COPD or worse (i.e. FEV1 < 50%); ≥ 4 exacerbations per year; ischemic heart disease; use of home O2; chronic oral corticosteroids; antibiotic use in the past 3 months.

- **Complicated UTIs:** lacks standard definition, but resistant organisms appear more likely if 1 or more of the following risk factors → signs and symptoms for greater than 7 days; male sex; renal failure; immunosuppression; diabetes (especially if long-term complications i.e. neuropathy); catheterization; structural abnormality; obstruction; recent urogenital procedure; spinal cord injury.

### Quick References

#### Antibiotics During Pregnancy/Lactation

<table>
<thead>
<tr>
<th>Antibiotics During Pregnancy/Lactation</th>
<th>Safe / Likely Safe / Caution / Contraindicated</th>
<th>1st Trimester</th>
<th>2nd Trimester</th>
<th>3rd Trimester</th>
<th>Lactation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FLUOROQUINOLONES</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erythromycin – non-estolate</td>
<td>safe</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erythromycin estolate</td>
<td>ILOSONE</td>
<td>risk of maternal hepatotoxicity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Azithromycin / Clarithromycin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amoxicillin + clav / Ampicillin</td>
<td>clavipenicillin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clindamycin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cotrimoxazole / SEPTRA, BACTRIM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sulfamethoxazole</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trimethoprim</td>
<td>I- folic acid</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metronidazole (oral)</td>
<td>1st trimester: accumulated data suggests likely safe</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nitrofurantoin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vancomycin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**MACRO**

| Macrolide                            |                                              |              |              |              |           |
| Erythromycin – non-estolate          | safe                                         |              |              |              |           |
| Erythromycin estolate                | no evidence of benefit                        |              |              |              |           |

**CEPHALOSPORINS**

<table>
<thead>
<tr>
<th>Cephalosporin</th>
<th>(available in Canada)</th>
<th>1st</th>
<th>2nd</th>
<th>3rd</th>
<th>4th</th>
</tr>
</thead>
<tbody>
<tr>
<td>cephalaxin (po)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cefadroxil (po)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cefazolin (I/M)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Cephalosporin Generations**

**In penicillin-allergic patients, how likely is cephalosporin cross-sensitivity?**

- In anaphylactic penicillin allergies, the risk of cross-reactivity with cephalosporins is low (1-2%); however, the usual recommendation is to avoid cephalosporins. (Some suggest that risk increases with similar side-chains - i.e. amoxicillin or ampicillin with cefazolin or cephalaxin; penicillin with cefixime.)
- In patients who have only had a penicillin rash, the risk of reaction is <0.1%. The usual recommendation is that cephalosporins are safe. Consider referral to an Allergy specialist.

Which antimicrobials are most associated with Clostridium difficile colitis?

Risk of *C. difficile* is essentially zero without antibiotic exposure. Most antibiotics carry some risk. Greatest risk appears to be with clindamycin (OR 16.8 vs no antibiotic exposure), cephalosporins, and fluoroquinolones.1,7

Which antimicrobials are most associated with QT prolongation?

For patients at risk of QT-prolongation, effect appears greatest with macrolides (clarithro, erythro > azithro) & fluoroquinolones (especially moxifloxacin and levofloxacin).

**Key Definitions:**

- **MAC:** mycobacterium avium complex
- **MIC:** minimum inhibitory concentration
- **MRSA:** methicillin-resistant *Staphylococcus aureus*
- **PEG:** polyethylene glycol
- **PK:** pharmacokinetics
- **SPR:** penicillin resistant
- **SAPS:** Simplified Acute Physiology Score
- **TEN:** toxic epidermal necrolysis
**Penicillin**: Binds to penicillin binding proteins on bacterial cell walls, inhibiting cell wall biosynthesis. Bactericidal. Demonstrates time-dependent killing.

- **AE**: rash, nausea, vomiting, diarrhea, melanglossia. **Rare**: allergic reactions, vomiting, diarrhea, nephritis. **Risk**: risk of SJS (but rare [] 2-3 per 100,000 patients).^6
- **Oral**: can ↑INR with warfarin; may cause oral contraceptive failure. **X**: signs of anaphylaxis. True penicillin anaphylactic allergy: 0.01% of population. **PK**: Amoxicillin and amox/clav have excellent bioavailability.

### Amoxicillin

**AMOXIL, g**

- 125, 250mg chew tab cherry
- 25, 50mg/mL susp strawberry, banana, sugar free, berry ☆
- 250, 500mg cap

1st trimester: ↑left lip/palate. Amoxicillin risk 2-4/1000 vs baseline risk of 1-2/1000

**Coverage**: *Streptococci; Enterococcus faecalis; Listeria; N. meningitidis.*

- **Useful in**: upper respiratory tract infections; sinusitus; acute otitis media; dental procedure prophylaxis; low-risk AECOPD. *Strep pneumo* resistance only 3% in Canada for community-treated infections.~

- **High pediatric doses (e.g. 90mg/kg/day) can overcame moderate *Strep pneumo* resistance in acute otitis media & community acquired pneumonia. Risk factors for PRSP: recent antibiotic use, daycare, not given PREVNAIR.

- **Consider watchful waiting in acute otitis media for suitable children (see page 78).**

- **Excellent bioavailability. Achieves high concentrations in the middle ear.**

**Dosing**

**Generic/TRADE** | **Adverse Events AE** | **Contraindications CI** | **Drug Interactions DI** | **Monitor M** | **Comments** | **Dosing (Adult, Pediatric, Usual Max)** | **$/10d** |
--- | --- | --- | --- | --- | --- | --- | --- |
Amoxicillin | | | | | | | |
2:1 (tab) q8h | $23 | | | | | | |
2:1 (sus) q8h | | | | | | | |
7:1 (tab, susp) q12h | $23 | | | | | | |
14:1 (combo) q12h | $69 | | | | | | |

**Amoxiclav ratio:**

- **1:2 (tab) q8h**: Adults: 250mg tab q8h
  - Often for less serious infections, or renal dysfunction (q12-24h).
  - Note: two 250mg tabs are not equal to one 500mg tab

- **4:1 (tab, susp) q8h**: Adults: 500mg tab q8h
  - Peds: 25, 50mg/mL susp rasp-orange dosed at 20-40mg/kg/day divided q8h

- **7:1 (tab, susp) q12h**: Adults: 875mg tab q12h
  - Peds: may give 875mg of suspension q12h if difficulty swallowing

- **14:1 (combo) q12h**: Peds: 40, 80mg/mL susp rasp-orange dosed at 45mg/kg/day divided q12h

**Discontinued**: Amoxicillin and amox/clav suspension. "May be needed in hospitalized pts for empiric coverage of gram-negative infections; also useful in an out-patient setting (e.g. one-time IM dose for gonorrhea; initial treatment of suspected pyelonephritis while waiting for cultures)."

### Cephalexin

**KEFLEX, g**

- 25, 50mg/mL orange-banana ☆
- 250, 500mg tab

**Coverage**: *Streptococci; MSSA; ?Proteus; E. coli; Klebsiella. (PEK)*

- **Useful in**: skin and soft tissue infections; step down option from IV cefazolin.

- **Take with food to reduce GI upset.**

**Dosing**

**Generic/TRADE** | **Adverse Events AE** | **Contraindications CI** | **Drug Interactions DI** | **Monitor M** | **Comments** | **Dosing (Adult, Pediatric, Usual Max)** | **$/10d** |
--- | --- | --- | --- | --- | --- | --- | --- |
Penicillin V Potassium | | | | | | | |
*PEN-VK, g* | | | | | | | |
25mg/mL sol'n fruity | | | | | | | |
60mg/mL sol'n fruity X Y | | | | | | | |
300mg(480,000 unit) tab | | | | | | | |

**Coverage**: *Streptococci; oral anaerobes (e.g. Actinomyces, Clostridium perfringens, Peptostreptococci, Propionibacterium). Still no resistance with Group A *Streptococcus* (aka *Streptococcus pyogenes).*

- **Useful in**: bacteraemia; rheumatic fever prophylaxis (prophylactic dose is 250mg po q12h)

- **q12h dosing in pharyngitis appears effective.**

**Cefuroxime axetil**

**CEFTIN, g**

- 25, 50mg/mL susp bubblegum ☆
- 250, 500mg tab

**Coverage**: *Streptococci; MSSA; Moraxella; Haemophilus influenzae; Proteus; E. coli; Klebsiella. (PEK)*

- **Useful in**: low-risk AECOPD; community-acquired pneumonia.

- **Cefuroxime has poor bioavailability (37% fasting; 52% with food).** Cefprozil has excellent bioavailability.

**Dosing**

**Generic/TRADE** | **Adverse Events AE** | **Contraindications CI** | **Drug Interactions DI** | **Monitor M** | **Comments** | **Dosing (Adult, Pediatric, Usual Max)** | **$/10d** |
--- | --- | --- | --- | --- | --- | --- | --- |
Ceftriaxone Injection | | | | | | | |
ROCEPHIN, g | | | | | | | |
1, 2, 10g vials for injection (IM/IV) X | | | | | | | |

**3rd-generation cephalosporin. Coverage: Streptococci; Moraxella; Haemophilus influenzae; ?Enterobacter; Neisseria; Proteus; E. coli; Klebsiella; Serratia. (HEN PECKS)**

- **Useful in**: gonorrhea (800mg po x1 dose + azitro); pyelonephritis or complicated UTIs; low-risk AECOPD.

**Peds**: 40-50mg/kg/day divided q8-12h
- 75-90mg/kg/day divided q8-12h if risk of *Strep pneumo* resistance max 3g/day

**Adult**: 500-1000mg po q8h
**Max**: 1000-4000mg/day

**Supra**: When targeting *Strep pneumo* in community-acquired pneumonia.

**Three 250mg tabs are not equal to one 500mg tab.**

**Coverage** (as per amoxicillin, plus: MSSA, many Enterobacteriaceae; *Streptococci* species). Gonorrhea resistance to cefixime ~ 2% in Canada (combine cefixime with a macrolide due to resistance + to add chlamydia coverage).

**AE**: rash, nausea, diarrhea. Rare: allergic reactions, cytopenias.

**Discontinued**: All cephalosporins lack coverage of *Listeria, atypicals, MRSA, & Enterococci (LAME).* Gonorrhea resistance to cefixime ~ 2% in Canada (combine cefixime with a macrolide due to resistance + to add chlamydia coverage).

**Discontinued Products**: Penicillin V Benzathine PEN-VEE suspension; cefaclor CECLOR tablet
### Macrolides
Inhibits bacterial protein synthesis. Bacteriostatic. Demonstrates time-dependent killing. Reserve when possible; useful for Streptococcal infections in context of beta-lactam allergy. **AI:** GI upset (erythromycin highest incidence); QT prolongation (clarithromycin = erythromycin > azithromycin); ↑LFTs; headache; insomnia. **Rare:** ototoxicity, infantile hypertrophic pyloric stenosis.

**Cl:** Caution in myasthenia gravis (possible association with muscle weakness).

**DI:** Clarithromycin and erythromycin CYP3A4 & p-glycoprotein inhibitors (clarithromycin > erythromycin) increased levels of alfuzosin, alprazolam, amitriptyline, amiodarone, apixaban, calcium channel blockers, colchicine, digoxin, haloperidol, midazolam, paroxetine, quetiapine, risperidone, rivanoxaban, sertraline, statins (atorvsa-, simva-, lova-statin), tamsulosin, tolterodine, warfarin, & others. See RxFiles Drug Interactions.

**LFTs:** CBC, LFTs, LFTs, CBC with prolonged therapy.

**No coverage of MRSA.** Minimal CNS penetration. **Streptococcus pneumoniae** resistance in SK (2015) = 20-30%; in Canada (2013) = 25%. Increased doses do not overcome **Streptococcus pneumoniae** resistance.

**Azithromycin**
ZITHROMAX, g
20, 40mg/mL susp cherry
250mg tab
500mg tab x

**Coverage:** Strep: *Streptococcus; N. gonorrhoeae; Moraxella; Haemophilus influenzae; Legionella; many atypicals.

**Useful in:** pneumonia; upper respiratory tract infections; low-risk AECOPD; MAC prophylaxis in HIV pts (but DIs with HIV medications possible).

**Keep reconstituted suspension at room temperature.**

**XL tab = with food & once daily.**

**Regular tab = with or without food.**

**Erythromycin, g**
ERYC 250, 333mg cap
Erythromycin base 250mg tab
Erythromycin Stearate 50mg/mL susp

**Coverage:** Strep: *Streptococcus; Moraxella; Legionella; many atypicals. (Unlike other macrolides, lacks H. influenzae coverage - therefore not recommended as empiric therapy for pneumonia in adults or in AECOPD. Reasonable option for pneumonia in kids < 12 years as H. influenzae uncommon in this group.)

**Useful in:** upper respiratory tract infections; acne; pneumonia if sensitive pathogen is cultured; pregnancy (non-estolate formulation).

**Has been used to increase GI motility e.g. in gastroparesis; but resistance concerns & development of tachyphyllaxis with long-term use limit this indication.**

**Estolate formulation: contraindicated in pregnancy (↑ hepatotoxicity), but best in kids as most acid stable.**

**Empty stomach ideal for increased absorption, but if not tolerated, taking with food decreases GI upset.**

**ERYC may be sprinkled on food.**

**Erythromycin unsafe in porphoria.**

**Tetracyclines**

**Ag:** GI upset (DOX = MIN < TET), vaginal candidiasis, photosensitivity (Dox > TET > MIN); esp. UVA, & dose-dependent i.e. less of a problem at DOX 100mg/day). Use Sunscreen SPF 15-30, especially if long-term use. **SIT up after taking for at least 30 minutes, and take with a full glass of water, to reduce risk of pills lodging in the esophagus and causing ulceration. MIN: hyperpigmentation of skin (rare bluish skin) & mucous membranes, lightheadedness, dizziness, vertigo, ataxia, drowsiness & fatigue. Serious: rare azotemia, pseudotumor cerebri (benign intracranial hypertension). MIN: rare lupus-like reaction, autoimmune hepatitis & hypersensitivity syndrome (case reports; implicated far more often in hypersensitivity reactions than other tetracyclines).

**Cl:** Pregnancy, Children < 9yrs, severe renal or hepatic dysfunction; DOX: myasthenia gravis (possible association with muscle weakness).

**GI absorption:** Fe**, Bismuth, Al**, Ca**, Mg** (separate dose by 2 hr); ↑INR and bleeding risk with warfarin; may ↓ oral contraceptive effectiveness; isotretinoin (intracranial hypertension/hemorrhage).

**M:** if using MIN long-term, consider LFTs & antinuclear factor baseline & q3-4 months.

**Tetracycline**
TETRACYCIN, g
200mg cap, tab

**Coverage:** Broad spectrum agents **Staphylococcus** (often MRSA); Strept pneumo; Moraxella; *Haemophilus influenzae*; many atypicals; many anaerobes including spirochetes.

**Useful in:** pneumonia; low-risk AECOPD, purulent skin & soft tissue infections; rickettsia; acne; Lyme disease **Better absorption on empty stomach (↑20%), but may take with food to improve tolerability if necessary.**

**Dosing at 100mg once daily OK in acne & malaria prophylaxis.**

**Minocycline**
MINOCIN, g
50, 100mg cap

**Coverage:** Broad spectrum agents **Staphylococcus; Strept pneumo; Moraxella; Haemophilus influenzae**; many atypicals; many anaerobes including spirochetes.

**Useful in:** some prosthetic joint infections; acne. **Due to association with serious rare AE, some suggest avoiding minocycline (doxycycline safer and effective).**

**Tetracycline**
TETRACYCIN, g
200mg cap

**Coverage:** Broad spectrum agents **Staphylococcus; Strept pneumo; Moraxella; Haemophilus influenzae**; many atypicals; many anaerobes including spirochetes.

**Useful in:** acne; actinomycosis; periodontitis. **Take TET on empty stomach - absorption is ↓ by food & dairy.**
### Oral Antibiotics (continued)

<table>
<thead>
<tr>
<th>Fluoroquinolones</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Adverse Events</strong> AE / <strong>Contraindications</strong> CI / <strong>Drug Interactions</strong> DI / <strong>Monitor</strong> M / <strong>Comments</strong></td>
</tr>
<tr>
<td><strong>Dosing</strong> (Adult, Pediatric, Usual Max)</td>
</tr>
<tr>
<td><strong>Price</strong></td>
</tr>
</tbody>
</table>

**Fluoroquinolones**

- Inhibits DNA-gyrase, causing breakdown of bacterial DNA. Bactericidal. Concentration dependent killing (aim for high peak concentrations).

**AE**

- GI upset; rash/photosensitivity; ↑QT; confusion/psychosis; ↑or ↓BG; seizure; tendinopathy/tendon rupture; retinal detachment; ↑weakness in myasthenia gravis; articular damage in kids; hepatotoxicity; nephrotoxicity.

**CI**

- CYP1A2 inhibition →↑levels of clozazepine, duloxetine, methotrexate, quinapril, rasagline, ropinirole, theophylline, tizanidine, varenicline, ↑INR with warfarin. QT prolongation (watch for other QT-prolonging agents).

- ↓absorption via chelation with Ca\(^{2+}\), Fe\(^{2+}\), Al\(^{3+}\), Mg\(^{2+}\) (may space calcium, iron, multivitamins, etc. by giving >2 hours after fluoroquinolone, or hold for duration of fluoroquinolone therapy). Binds to enteral tube feeds (due to cations in feed - calcium, iron, etc.). May have less absorption via jejunostomy tube since fluoroquinolones are likely absorbed in the duodenum. Increased risk of tendon rupture when given with corticosteroids.

**DI**

- Increase in absorption of the following through P-gp inhibition: CYP1A2 substrates (e.g. carvedilol, digoxin, phenytoin, rifampin). ↑hyperkalemia risk with >3-5d of therapy, elderly, CKD, HF, DM, meds ↑K\(^+\), ↓Na\(^+\), ↑SCR (often mild/transient), ↓BG.

- Common: nausea, vomiting, skin reactions (photosensitivity; rash; pruritus; rare: SJS/TEN, SCr (often mild/transient), 12↑K\(^+\) by 3A4 inducers (e.g. ACEI, ARB, spironolactone, eplerenone, NSAIDs, prednisone).

- Rare (due to ↑hyperkalemia in elderly patients): taking other drugs known to increase potassium (see DI section below). 15-24 Reports of sudden death (due to ↑hyperkalemia) in elderly patients taking other drugs known to increase potassium (see DI section below).

- Caution: patients with G6PD deficiency (risk of hemolysis); patients with porphyria; infants <2 months of age.

- M: CBC, K\(^+\) (if >3-5d of therapy), SCr, BUN.

**Antifolates**

- Prevent bacterial folate synthesis. Sulfamethoxazole & trimethoprim inhibit successive steps in folic acid pathway, & thus are synergistic in combination. Combination bactericidal; concentration-dependent killing.

**AE**

- Generally well tolerated. Common: nausea, vomiting, skin reactions (photosensitivity; rash; pruritus; rare: SJS/TEN → 3 per 100,000 patients), ↑headache, ↑K\(^+\), ↓Na\(^+\), ↑SCR (often mild/transient), ↓BG.

**CI**

- History of drug induced-immune thrombocytopenia from sulfonamides or trimethoprim; megaloblastic anemia from folate deficiency; severe liver disease; previous SJS from sulfonamides.

**Notes:**

- **Restrictions:** Gatifloxacin & moxifloxacin are also indicated for eye infections. Ofloxacin may be added to fluoroquinolones for coverage of chlamydia & mycoplasma (may cause photophobia). Trimethoprim & sulfamethoxazole are contraindicated in epidermolysis bullosa patients due to risk of skin detachment.

- Discontinued Products: Gemifloxacin FACTIVE tab; Ofloxacin FLOXIN tab; Trovafloxacin TROVAN tab [hepatic adverse events]; Gatifloxacin TEQUIN tab [increased diabetes]; Grepafloxacin REXAR tab [increased cardiac events].

---

**Fluoroquinolone use discouraged in <18 yrs.**

**Ciprofloxacin**

- **CIPRO, g**

**Peds:** 20-30mg/kg/day po divided q12h $29

**Adult:** 500mg po q12h (or 1000mg XL daily) separate from dairy $26

**Max:** 1500mg/day $33

**Levofloxacin**

- **LEVAQUIN, g**

**Peds:** 8-10mg/kg po q24h $31

**Adult:** 500-750mg po q24h separate from dairy $29-45

**Max:** 750mg/day $45

**Moxifloxacin**

- **AVELOX, g**

**Peds:** not indicated -

**Adult:** 400mg po q24h separate from dairy $28

**Max:** 400mg/day $28

**Norfloxacin**

- **NOROXIN, g**

**Peds:** not indicated -

**Adult:** 400mg po q12h separate from dairy $23

**Max:** 800mg/day $23

---

**Sulfamethoxazole/Trimethoprim**

- **BACTRIM, SEPTA, Cotrimoxazole, g**

**Peds:** 6-12mg/kg/day TMP po divided q12h $21

**Adult:** 800/160mg po q12h $13

**Max:** 320mg/day of TMP component $13

**Trimethoprim**

- **PROLOPRIM, g**

**Peds:** 10mg/kg/day po divided q12h $17

**Adult:** 100mg po q12h $17

**Max:** 200mg/day $17

---

**Notes:**

- **Restricted to Clinically stable patients.**

- **Discontinued Products:** Gemifloxacin FACTIVE tab; Ofloxacin FLOXIN tab; Trovafloxacin TROVAN tab [hepatic adverse events]; Gatifloxacin TEQUIN tab [increased diabetes]; Grepafloxacin REXAR tab [increased cardiac events].
<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Adverse Events</th>
<th>AE / Contraindications</th>
<th>CI / Drug Interactions</th>
<th>Dosing (Adult, Pediatric, Usual Max)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clindamycin</td>
<td>DOLACIN C, g</td>
<td>Inhibits bacterial protein synthesis. Bacteriostatic; time-dependent killing. <strong>Coverage</strong>: Staphylococci, Streptococci; many oral anaerobes. Unreliable MRSA coverage and indubable Staph &amp; Strep resistance.</td>
<td>Useful in: skin and soft tissue infections; dental infections (although usually safer options). Reduces toxin production of Streptococci and Staphylococci (e.g. useful to toxic shock syndrome in necrotizing fasciitis - give in combination with penicillin).</td>
<td>Adult: 10-30mg/kg/day po divided q6h</td>
<td>$34</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>AE: nausea, diarrhea, rash (rare: SJS), ↑LFTs. Rare: leukopenia, thrombocytopenia. Higher risk of Clostridium difficile than other agents. AE profile plus increasing resistance (including inducible D-zone) limits role.</td>
<td>DL: May decrease effect of erythromycin (competitive binding to same bacteria protein site).</td>
<td>Adult: 300-450mg po q6-8h</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>DR: Not for use in patients with severe oropharyngeal infection who require treatment with clindamycin.</td>
<td>Max: 1800mg/day</td>
<td>$39</td>
</tr>
<tr>
<td>Metronidazole</td>
<td>FLAGYL, g</td>
<td>Disrupts DNA of bacterial cells. Bactericidal. <strong>Coverage</strong>: most anaerobes, including anaerobic protozoa.</td>
<td>Useful in: intra-abdominal infections; C difficile; bacterial vaginosis; trichomoniasis; diabetic foot infections.</td>
<td>Adult: 15mg/mL sol'n cherry</td>
<td>Drug of choice in mild-to-moderate (i.e. WBC&lt;15 &amp; CR=1.5x baseline) initial or first-recurrence C. difficile infections. Dose = 500mg TID po x 10-14 days.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>AE: GI upset, metallic taste, headache, vaginitis, peripheral/optic neuropathy (long-term use). Rare: neurotoxicity, leukopenia, skin reactions (rash, pruritus, SJS/TEN).</td>
<td>CI: Use of disulfiram in previous 2 weeks; avoid medication for at least 1 week after therapy and 3 days after administration.</td>
<td>Adult: 250-500mg po q8-12h</td>
</tr>
<tr>
<td></td>
<td>Nitrofurantoin</td>
<td>MACRODANTIN, g</td>
<td>Damages bacterial DNA/proteins (bacteria convert nitrofurantoin into reactive forms). Multiple sites of attack slow to develop. <strong>Coverage</strong>: Staphylococci; E. coli; Enterococcus faecalis; Citrobacter; Klebsiella.</td>
<td>Useful in: First-line therapy in UTIs. Only 5 days needed if uncomplicated. Avoid if suspected pyelonephritis.</td>
<td>Adult: 10mg/kg/day divided q8h</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fosfomycin</td>
<td>MONUROL</td>
<td>Inhibits cell-wall formation. Bactericidal. <strong>Coverage</strong>: ?Staphylococci; Enterococci; Enterobacteriaceae. Often coverage even if multi-drug resistance (MRSA, ESBL-producing organisms, VRE).</td>
<td>Useful in: UTIs. Avoid if suspected pyelonephritis. Safe in pregnancy but usually better options.</td>
<td>Adult: 2000mg x 1 dose</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Linezolid</td>
<td>ZYVOXAM, g</td>
<td>Inhibits bacterial protein synthesis. Usually bacteriostatic, but bactericidal against Streptococci. <strong>Coverage</strong>: Streptococci; Enterococci (including VRE); Staphylococci (including MRSA).</td>
<td>Useful in: multi-drug resistant infections (including pneumonia, skin and soft tissue, etc.).</td>
<td>Adult: 30mg/kg/day po divided q12h</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Probenecid</td>
<td>BENURYL</td>
<td>Prolongs penicillin levels by competitively inhibiting their excretion. Give 30-45min prior to IV penicillin dose.</td>
<td>Occasionally useful if IV therapy is needed in an outpatient setting to ▶ convenience / ▶ home care visits (e.g. in syphilis to penicillin dosing to q24h IM; in cellulitis to IV cefazolin dosing to q24h).</td>
<td>Adult: 40mg/kg/day po divided q6h</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vancomycin</td>
<td>VANCOCIN, g</td>
<td>Inhibits cell-wall formation. <strong>Coverage</strong>: The only oral use is for treatment of Clostridium difficile colitis (drug of choice if severe infection or, if second recurrence of C. difficile infection; 1st taper over ~8wks in recurrent infections).</td>
<td>Rare when used po. X: Usually no significant drug interactions. X: Essentially no oral absorption (used po for local effect in bowel); however, dialysis patients may require a random vancomycin level if toxicity suspected.</td>
<td>Adult: 40mg/kg/day po divided q6h</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Methenamine mandelate: MANDELAMINE 500mg po q6h S33 | Creates acidic urine; indicated for UTI prophylaxis, but not first line (limited evidence); likely inefficacious in catheterized patients; X: rash, GI upset, bladder irritation, ♦/LFTs; ▶/agonists, β-agonists, amphetamines, sulfonamides, acetazolamide, antacids; U: Urination, periodic LFTs; ▶: severe hepatic dysfunction, gout.


Saskatchewan Antiibiograms: Regina [www.rqhealth.ca/clinical-support/Antibiograms]; Saskatoon [www.saskatoonhealthregion.ca/locations_services/Services/Pathology-Laboratory-Med/healthpractitioners/Pages/antibiograms.aspx]

Probiotics: includes Saccharomyces boulardii, Lactobacillus rhamnosus GG, others. ▼ antibiotic-associated diarrhea; separate >2hrs from antibiotics; S. boulardii 1g daily for C. difficile diarrhea (caution: immunocompromised, pancreatitis).
CASE DISCUSSIONS

ACUTE UNCOMPROMICATED CYSTITIS

A 25 year old female presents with a 36-hour history of dysuria, frequency and urgency. She does not have any fever or other generalized symptoms.

- Med Hx
  - medical history unremarkable
  - sexually active with 1 partner
  - medications: an oral contraceptive
  - no hx of antibiotics in last 5 years
  - no allergies

- Physical Examination
  - suprapubic discomfort
  - no costovertebral angle tenderness
  - no fever or chills

- Treatment Options (alphabetical)
  - Amoxicillin  x ____ days
  - Amox/Clavulanic  x ____ days
  - Cephalexin  x ____ days
  - Ciprofloxacin  x ____ days
  - Fosfomycin  x ____ days
  - Nitrofurantoin  x ____ days
  - Norfloxacin  x ____ days
  - TMP/SMX  x ____ days
  - Trimethoprim  x ____ days

- What if...
  - she had one previous similar episode 6 weeks earlier?
  - she has a previous hx of 5 such infections in the past year?
  - she returns in 5 days with new & worsening symptoms?

SKIN & SOFT TISSUE INFECTION

A 25 year old male presents with pain and inflammation to his lower leg. This has evolved over a few days following a scrape while doing yard work. He has been active at work and in sports since the accident, but his leg is more painful today.

- Med Hx
  - generally healthy, a non-smoker
  - “allergy to penicillin” (he had a rash while on amoxicillin as a child)
  - not taking any medication

- Physical Examination
  - distal 1/3 leg: warm, red, swollen 8 cm area of skin surrounding a small dry abrasion above medial malleolus; no fluctuation; no lymphangitis
  - afebrile
  - appearance consistent with cellulitis

- Treatment Options (alphabetical)
  - Cephalexin  x ____ days
  - Clarithromycin  x ____ days
  - Cloxacillin  x ____ days
  - Doxycycline  x ____ days
  - Other  x ____ days
  - Polysporin topical  x ____ days
  - TMP/SMX  x ____ days
  - Rest, elevate leg  □ Medical certificate for work

- What if...
  - he has signs of an abscess?
  - he is on the wrestling team?
  - he is febrile?

COMING UP FALL 2017: OPIOIDS

RxFiles: Celebrating 20 Years

As of April 2017, we are celebrating 20 years of academic detailing in Saskatchewan. A lot has changed over two decades, and we have grown with the changes. One thing that remains the same is our commitment to bringing evidence to practice through friendly, informative face to face discussions. What you see in print is just a tool to support these discussions and help them to inform practice long after they are done. Thank you to everyone in Saskatchewan who has supported us.

Your input and participation is at the heart of RxFiles!!!

We value: quality evidence, clinical experience, cost effectiveness, practical considerations including patient & societal values. It’s all in the detail!!

ACKNOWLEDGEMENTS (continued...) The rest of the RxFiles academic detailing team (Zack Dumont, Vaughn Johnson, Tanya Nyström, Lisa Rutherford, Brenda Schuster, Pam Karlson). Although many contributed to this topic workup, Lynette Kosar took the initial lead on the 4 primary therapeutic topics, including overseeing related resident rotations. Thank you Lynette!!!

Graphic Design: Debbie Bunka, Colette Molyne (designmoly.com)

Disclaimer: The content of this newsletter represents the research, experience and opinions of the authors and not those of the Board or Administration of Saskatchewan Health Region (SHR). Neither the authors nor Saskatchewan Health Region nor any other party who has been involved in the preparation or publication of this work warrants or represents that the information contained herein is accurate or complete, and they are not responsible for any errors or omissions or for the result obtained from the use of such information. Any use of the newsletter will imply acknowledgment of this disclaimer and release any responsibility of SHR, its employees, servants or agents. Readers are encouraged to confirm the information contained herein with other sources.

Additional information and references online at www.RxFiles.ca; www.RxFiles.ca/ABX; Copyright 2017 – RxFiles, Saskatchewan Health Region (SHR)

ACKNOWLEDGEMENTS (more details online)

RxFiles is very pleased to acknowledge those who contributed to ABX Part 2 topic development & review.

Overall ABX Topic/Project Guidance: Lynette Kosar Pharmacist, RxFiles Loren Regier Pharmacist, RxFiles Tessa Laubscher Family Physician, Saskatoon Yvonne Shevchuk UofS, College of Pharmacy Pam Komonoski, RN(NP) UofS Student Health Linda Sulz Pharmacist, RQHR Justin Kosar Pharmacist, SHR Stewardship Casey Phillips Pharmacist, RQHR Stewardship

Content Development: Lynette Kosar* Marlys LeBras Loren Regier Pharmacists, RxFiles Co-Leads Alex Crawley Pharmacist, RxFiles Jeff Herbert Pharmacy Resident, SHR Alicia Gauthier Pharmacy Resident, SHR

Topic Input &/or Review: James Irvin, MD, FHM, Northern SK Lindsay Nicolle, MD, Infectious Disease Kishore Visvanathan, MD, Urology Annette Epp, MD, Gynecology Brent Jensen Pharmacist, RxFiles Jessica Minion RQHR Microbiology Jill Blaser-Farrukh Family Physician, Saskatoon Joe Blondeau SHR Microbiology Marlys LeBras Pharmacist, RxFiles Nora McKee Family Physician, Saskatoon Reid McGregor Family Physician, Northern SK Roger Bristol Emergency Med, SHR Shaquil Peer Mohammad MD, SHR Infectious Disease Alexander Wong MD, RQHR Infectious Disease

Coming up Fall 2017: OPIOIDS
Details That Matter
~
Objective & Evidence-based Drug Information

Drug Comparison Charts
11th Edition

App / Online Subscription also available

Follow Us: through email updates

OR

ON:

Geri-RxFiles 2nd Edition

Assessing Medications in Older Adults
Alternatives to explore, when less may be more

www.RxFiles.ca

November 2015 2nd Edition

www.RxFiles.ca

It’s all in the detail!
Objective Comparative
Drug Information

www.RxFiles.ca